Synthesis of Radiometal-Labeled and Fluorescent Cell-Permeating Peptide-PNA Conjugates for Targeting the bcl-2 Proto-oncogene

Bioconjugate Chemistry

Volumn 14, Issue 6, 2003, Pages 1083-1095

  Gallazzi, Fabio ^a   Wang, Yi ^a   Jia, Fang ^a   Shenoy, Nalini ^a   Landon, Linda A ^b   Hannink, Mark ^b   Lever, Susan Z ^a   Lewis, Michael R ^a,b,c  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CHELATION; CHEMOTHERAPY; DIAGNOSIS; FLUORESCENCE; FLUORESCENCE MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MAMMALS; NUCLEIC ACIDS; PLASMA STABILITY; SYNTHESIS (CHEMICAL);

ANTISENSE PEPTIDES; B-CELL LYMPHOMA/LEUKEMIA-2; CELLULAR INTERNALIZATION; FLUORESCENT CELLS; LABELED CELLS; PEPTIDE NUCLEIC ACID; PEPTIDE SEQUENCES; PROTO-ONCOGENES; SYNTHESISED; SYNTHETIC STRATEGIES;

PEPTIDES;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 9 FLUORENYLMETHYL CHLOROFORMATE; CHELATING AGENT; DNA; GLYCINE DERIVATIVE; LYSINE; METAL; MONOMER; PEPTIDE NUCLEIC ACID; PROTEIN BCL 2;

ARTICLE; AUTOMATION; CHELATION; CODON; CONFOCAL MICROSCOPY; DNA SEQUENCE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHOBICITY; ISOTOPE LABELING; MAMMALIAN GENETICS; MOLECULE; NONHUMAN; ONCOGENE; OPEN READING FRAME; PLASMA; PURIFICATION; SOLID; TEMPERATURE;

MAMMALIA;

EID: 0344494687     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc034084n     Document Type: Article

References (58)

1. Milas, L., Stephens, L. C., and Meyn, R. E. (1994) Relation of Apoptosis to Cancer Therapy. In Vivo 8, 665-674.
2. Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., and Korsmeyer, S. J. (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348, 334-336.
3. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J. (1993) Bcl-2 Heterodimerizes In Vivo with a Conserved Homolog, Bax, That Accelerates Programmed Cell Death. Cell 74, 609-619.
4. Miyashita, T., and Reed, J. C. (1992) bcl-2 Gene Transfer Increases Relative Resistance of S49.1 and WEHI7.2 Lymphoid Cells to Cell Death and DNA Fragmentation Induced by Glucocorticoids and Multiple Chemotherapeutic Drugs. Cancer Res. 52, 5407-5411.
5. Miyashita, T., and Reed, J. C. (1993) Bcl-2 Oncoprotein Blocks Chemotherapy-Induced Apoptosis in a Human Leukemia Cell Line. Blood 81, 151-157.
6. Reed, J. C., Kitada, S., Takayama, S., and Miyashita, T. (1994) Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann. Oncol. 5, S61-S65.
7. Sentman, C. L., Shutter, J. R., Hockenbery, D., Kanagawa, O., and Korsmeyer, S. J. (1991) bcl-2 Inhibits Multiple Forms of Apoptosis but Not Negative Selection in Thymocytes. Cell 67, 879-888.
8. Strasser, A., Harris, A. W., and Cory, S. (1991) bcl-2 Transgene Inhibits T Cell Death and Perturbs Thymic Self-Censorship. Cell 67, 889-899.
9. Mirkovic, N., Voehringer, D. W., Story, M. D., McConkey, D. J., McDonnell, T. J., and Meyn, R. E. (1997) Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols. Oncogene 15, 1461-1470.
10. Tsujimoto, Y., Cossman, J., Jaffe, E., and Croce, C. M. (1985) Involvement of the bcl-2 Gene in Human Follicular Lymphoma. Science 228, 1440-1443.
11. Yunis, J. J., Oken, M. M., Kaplan, M. E., Ensrud, K. M., Howe, R. R., and Theologides, A. (1982) Distinctive Chromosomal Abnormalities in Histologic Subtypes of Non-Hodgkin's Lymphoma. N. Engl. J. Med. 307, 1231-1236.
12. Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C., and Croce, C. M. (1984) Cloning of the Chromosome Breakpoint of Neoplastic B Cells with the t(14;18) Chromosome Translocation. Science 226, 1097-1099.
13. Levine, E. G., Arthur, D. C., Frizzera, G., Peterson, B. A., Hurd, D. D., and Bloomfield, C. D. (1985) There Are Differences in Cytogenetic Abnormalities Among Histologic Subtypes of the Non-Hodgkin's Lymphomas. Blood 66, 1414-1422.
14. Pezzella, F., Tse, A. G. D., Cordell, J. L., Pulford, K. A. F., Gatter, K. C., and Mason, D. Y. (1990) Expression of the bcl-2 Oncogene Protein Is Not Specific for the 14; 18 Chromosomal Translocation. Am. J. Pathol. 137, 225-232.
15. Zutter, M., Hockenbery, D., Silverman, G. A., and Korsmeyer, S. J. (1991) Immunolocalization of the Bcl-2 Protein Within Hematopoietic Neoplasms. Blood 78, 1062-1068.
16. Karakas, T., Maurer, U., Weidmann, E., Miething, C. C., Hoelzer, D., and Bergmann, L. (1998) High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann. Oncol. 9, 159-165.
17. Puthier, D., Pellat-Deceunynck, C., Barillé, S., Robillard, N., Rapp, M.-J., Juge-Morineau, N., Harousseau, J.-L., Bataille, R., and Amiot, M. (1999) Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy. Leukemia 13, 289-294.
18. Lanzafame, S., Emmanuele, C., Torrisi, A., and Magro, G. (1998) Correlated Expression of BCL-2 Protein, Estrogen Receptor, Cathepsin D and Low Growth Fraction (PCNA) in Intracystic Papillary Breast Carcinoma. Pathol. Res. Pract. 194, 541-547.
19. Pezzella, F., Turley, H., Kuzu, I., Tungekar, M. F., Dunnill, M. S., Pierce, C. B., Harris, A., Gatter, K. C., and Mason, D. Y. (1993) bcl-2 Protein in Non-Small-Cell Lung Carcinoma. N. Engl. J. Med. 329, 690-694.
20. Jiang, S.-X., Sato, Y., Kuwao, S., and Kameya, T. (1995) Expression of bcl-2 Oncogene Protein is Prevalent in Small Cell Lung Carcinomas. J. Pathol. 177, 135-138.
21. Sinicrope, F. A., Ruan, S. B., Cleary, K. R., Stephens, L. C., Lee, J. J., and Levin, B. (1995) bcl-2 and p53 Oncoprotein Expression during Colorectal Tumorigenesis. Cancer Res. 55, 237-241.
22. Yang, H.-B., Chow, N.-H., Sheu, B.-S., Chan, S.-H., Chien, C.-H., and Su, I.-J. (1999) The Role of bcl-2 in the Progression of the Colorectal Adenoma-Carcinoma Sequence. Anticancer Res. 19, 727-730.
23. Colombel, M., Symmans, F., Gil, S., O'Toole, K. M., Chopin, D., Benson, M., Olsson, C. A., Korsmeyer, S., and Buttyan, R. (1993) Detection of the Apoptosis-Suppressing Oncoprotein bcl-2 in Hormone-Refractory Human Prostate Cancers. Am. J. Pathol. 143, 390-400.
24. Sullivan, G. F., Amenta, P. S., Villanueva, J. D., Alvarez, C. J., Yang, J.-M., and Hait, W. N. (1998) The Expression of Drug Resistance Gene Products during the Progression of Human Prostate Cancer. Clin. Cancer Res. 4, 1393-1403.
25. Wang, D.-G., Johnston, C. F., and Buchanan, K. D. (1997) Oncogene Expression in Gastroenteropancreatic Neuroendocrine Tumors. Implications for Pathogenesis. Cancer 80, 668-675.
26. Cerroni, L., Soyer, H. P., and Kerl, H. (1995) bcl-2 Protein Expression in Cutaneous Malignant Melanoma and Benign Melanocytic Nevi. Am. J. Dermatopathol. 17, 7-11.
27. Hermine, O., Haioun, C., Lepage, E., d'Agay, M.-F., Briere, J., Lavignac, C., Fillet, G., Salles, G., Marolleau, J.-P., Diebold, J., Reyes, F., and Gaulard, P. (1996) Prognostic Significance of bcl-2 Protein Expression in Aggressive Non-Hodgkin's Lymphoma. Blood 87, 265-272.
28. Hill, M. E., MacLennan, K. A., Cunningham, D. C., Vaughan Hudson, B., Burke, M., Clarke, P., Di Stefano, F., Anderson, L., Vaughan Hudson, G., Mason, D., Selby, P., and Linch, D. C. (1996) Prognostic Significance of BCL-2 Expression and bcl-2 Major Breakpoint Region Rearrangement in Diffuse Large Cell Non-Hodgkin's Lymphoma: A British National Lymphoma Investigation Study. Blood 88, 1046-1051.
29. Alas, S., Emmanouilides, C., and Bonavida, B. (2001) Inhibition of Interleukin 10 by Rituximab Results in Down-Regulation of Bcl-2 and Sensitization of B-Cell Non-Hodgkin's Lymphoma to Apoptosis. Clin. Cancer Res. 7, 709-723.
30. Alas, S., and Bonavida, B. (2001) Rituximab Inactivates Signal Transducer and Activation of Transcription 3 (STAT3) Activity in B-Non-Hodgkin's Lymphoma through Inhibition of the Interleukin 10 Autocrine/Paracrine Loop and Results in Down-Regulation of Bcl-2 and Sensitization to Cytotoxic Drugs. Cancer Res. 61, 5137-5144.
31. Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N., and Bonavida, B. (1997) Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs. Cancer Biother. Radiopharm. 12, 177-186.
32. Witzig, T. E. (2001) Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma. Cancer Chemother. Pharmacol. 48 (Suppl 1), S91-S95.
33. 67Cu-2IT-BAT-Lym-1 Therapy on BCL-2 Gene and Protein Expression in a Lymphoma Mouse Model. Clin. Cancer Res. (Suppl.) 5, 3010s-3014s.
34. Cotter, F. E., Johnson, P., Hall, P., Pocock, C., Al Mahdi, N., Cowell, J. K., and Morgan, G. (1994) Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 9, 3049-3055.
35. Webb, A., Cunningham, D., Cotter, F., Clarke, P. A., di Stefano, F., Ross, P., Corbo, M., and Dziewanowska, Z. (1997) BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349, 1137-1141.
36. Jansen, B., Wacheck, V., Heere-Ress, E., Schlagbauer-Wadl, H., Hoeller, C., Lucas, T., Hoermann, M., Hollenstein, U., Wolff, K., and Pehamberger, H. (2000) Chemosensitization of malignant melanoma by BCL2 antisense therapy. Lancet 356, 1728-1733.
37. Nielsen, P. E., Egholm, M., Berg, R. H., and Buchardt, O. (1991) Sequence Selective Recognition of DNA by Strand Displacement with a Thymine-substituted Polyamide. Science 254, 1497-1500.
38. Larsen, H. J., Bentin, T., and Nielsen, P. E. (1999) Antisense properties of peptide nucleic acid. Biochim. Biophys. Acta 1489, 159-166.
39. Aldrian-Herrada, G., Desarménien, M. G., Orcel, H., Boissin-Agasse, L., Méry, J., Brugidou, J., and Rabié, A. (1998) A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a retro-inverso delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons. Nucleic Acids Res. 26, 4910-4916.
40. Pooga, M., Soomets, U., Hällbrink, M., Valkna, A., Saar, K., Rezaei, K., Kahl, U., Hao, J.-X., Xu, X.-J., Wiesenfeld-Hallin, Z., Hökfelt, T., Bartfai, T., and Langel, U. (1998) Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol. 16, 857-861.
41. Koppelhus, U., Awasthi, S. K., Zachar, V., Holst, H. U., Ebbesen, P., and Nielsen, P. E. (2002) Cell-Dependent Differential Cellular Uptake of PNA, Peptides, and PNA-Peptide Conjugates. Antisense Nucleic Acid Drug Dev. 12, 51-63.
42. Braun, K., Peschke, P., Pipkorn, R., Lampel, S., Wachsmuth, M., Waldeck, W., Friedrich, E., and Debus, J. (2002) A Biological Transporter for the Delivery of Peptide Nucleic Acids (PNAs) to the Nuclear Compartment of Living Cells. J. Mol. Biol. 318, 237-243.
43. Kaushik, N., Basu, A., Palumbo, P., Myers, R. L., and Pandey, V. N. (2002) Anti-TAR Polyamide Nucleotide Analogue Conjugated with a Membrane-Permeating Peptide Inhibits Human Immunodeficiency Virus Type 1 Production. J. Virol. 76, 3881-3891.
44. Derossi, D., Joliot, A. H., Chassaing, G., and Prochiantz, A. (1994) The Third Helix of the Antennapedia Homeodomain Translocates through Biological Membranes. J. Biol. Chem. 269, 10444-10450.
45. Fawell, S., Seery, J., Daikh, Y., Moore, C., Chen, L. L., Pepinsky, B., and Barsoum, J. (1994) Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. U.S.A. 91, 664-668.
46. Ho, A., Schwarze, S. R., Mermelstein, S. J., Waksman, G., and Dowdy, S. F. (2001) Synthetic Protein Transduction Domains: Enhanced Transduction Potential in Vitro and in Vivo. Cancer Res. 61, 474-477.
47. Lewis, M. R., Jia, F., Gallazzi, F., Wang, Y., Zhang, J., Shenoy, N., Lever, S. Z., and Hannink, M. (2002) Radiometal-Labeled Peptide-PNA Conjugates for Targeting bcl-2 Expression: Preparation, Characterization, and in Vitro mRNA Binding. Bioconjugate Chem. 13, 1176-1180.
48. Thiers, R. E. (1957) Contamination in Trace Element Analysis and Its Control Methods. Biochem. Anal. 5, 273-335.
49. Eriksson, M., Christensen, L., Schmidt, J., Haaima, G., Orgel, L., and Nielsen, P. E. (1998) Sequence dependent N-terminal rearrangement and degradation of peptide nucleic acid (PNA) in aqueous solution. New J. Chem. 22, 1055-1059.
50. Volkert, W. A., and Hoffman, T. J. (1999) Therapeutic Radiopharmaceuticals. Chem. Rev. 99, 2269-2292.
51. Graninger, W. B., Seto, M., Boutain, B., Goldman, P., and Korsmeyer, S. J. (1987) Expression of Bcl-2 and Bcl-2-Ig Fusion Transcripts in Normal and Neoplastic Cells. J. Clin. Invest. 80, 1512-1515.
52. Richard, J. P., Melikov, K., Vives, E., Ramos, C., Verbeure, B., Gait, M. J., Chernomordik, L. V., and Lebleu, B. (2003) Cell-penetrating Peptides. A Reevaluation of the Mechanism of Cellular Uptake. J. Biol. Chem. 278, 585-590.
53. Moulton, H. M., and Moulton, J. D. (2003) Peptide-assisted delivery of steric-blocking antisense oligomers. Curr. Opin. Mol. Ther. 5, 123-132.
54. Vives, E., Richard, J. P., Rispal, C., and Lebleu, B. (2003) TAT Peptide Internalization: Seeking the Mechanism of Entry. Curr. Protein Pept. Sci. 4, 125-132.
55. Dom, G., Shaw-Jackson, C., Matis, C., Bouffioux, O., Picard, J. J., Prochiantz, A., Mingeot-Leclercq, M.-P., Brasseur, R., and Rezsohazy, R. (2003) Cellular uptake of Antennapedia Penetratin peptides is a two-step process in which phase transfer precedes a tryptophan-dependent translocation. Nucleic Acids Res. 31, 556-561.
56. Thorén, P. E. G., Persson, D., Isakson, P., Goksör, M., Önfelt, A., and Nordén, B. (2003) Uptake of analogues of penetratin, Tat(48-60), and oligoarginine in live cells. Biochem. Biophys. Res. Commun. 307, 100-107.
57. Violini, S., Sharma, V., Prior, J. L., Dyszlewski, M., and Piwnica-Worms, D. (2002) Evidence for a Plasma Membrane-Mediated Permeability Barrier to Tat Basic Domain in Well-Differentiated Epithelial Cells: Lack of Correlation with Heparan Sulfate. Biochemistry 41, 12652-12661.
58. Gammon, S. T., Villalobos, V. M., Prior, J. L., Sharma, V., and Piwnica-Worms, D. (2003) Quantitative Analysis of Permeation Peptide Complexes Labeled with Technetium-99m: Chiral and Sequence-Specific Effects on Net Cell Uptake. Bioconjugate Chem. 14, 368-376.